DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,920.00
-205.00 (-4.97%)
At close: Jun 19, 2026
Market Cap106.01B -31.0%
Revenue (ttm)242.08B -0.7%
Net Income50.38B
EPS1,769.06
Shares Out 27.04M
PE Ratio2.22
Forward PEn/a
Dividend120.00 (3.06%)
Ex-Dividend DateDec 29, 2025
Volume107,275
Open4,125.00
Previous Close4,125.00
Day's Range3,880.00 - 4,130.00
52-Week Range3,800.00 - 6,390.00
Beta0.36
Analystsn/a
Price Targetn/a
Earnings DateMay 28, 2026

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip... [Read more]

Industry Pharmaceutical Preparations
Founded 1970
Employees 404
Stock Exchange KOSDAQ
Ticker Symbol 006620
Full Company Profile

Financial Performance

In 2025, DongKoo Bio & Pharma's revenue was 242.69 billion, a decrease of -2.64% compared to the previous year's 249.27 billion. Earnings were 50.27 billion, an increase of 2369.74%.

Financial Statements